

## RSC Communicable and Respiratory Disease Report for England

### Key Statistics:

Week Number/Year..... 46/2024  
 Week Starting - Ending..... 11/11/2024 - 17/11/2024  
 No. of Practices..... 1,688  
 Population..... 17,862,856

### National (England)

- **Acute Respiratory Infections:** increased from **280.6** in week 45 to **295.0** in week 46.
- **Influenza-like illness:** decreased from **3.8** in week 45 to **3.7** in week 46.
- **Exacerbations of Chronic Lung Disease:** was unchanged at **22.9** in week 45 and **22.9** in week 46.
- **Lower Respiratory Tract Infections:** increased from **104.6** in week 45 to **109.1** in week 46.
- **Upper Respiratory Tract Infections:** increased from **165.2** in week 45 to **176.6** in week 46.
- **COVID-19:** decreased from **2.3** in week 45 to **1.5** in week 46.

### Regional (North, South, London and Midlands and East)

- **Acute Respiratory Infections:** increased from **216.9** in week 45 to **237.4** in week 46 in the London region, increased from **341.6** in week 45 to **356.5** in week 46 in the North region, increased from **261.0** in week 45 to **266.1** in week 46 in the South region, and increased from **297.8** in week 45 to **317.9** in week 46 in the Midlands And East region.
- **Influenza-like illness:** increased from **4.2** in week 45 to **4.8** in week 46 in the London region, decreased from **4.5** in week 45 to **3.9** in week 46 in the North region, decreased from **3.4** in week 45 to **3.1** in week 46 in the South region, and increased from **3.3** in week 45 to **3.6** in week 46 in the Midlands And East region.
- **Exacerbations of Chronic Lung Disease:** increased from **13.3** in week 45 to **13.4** in week 46 in the London region, increased from **31.5** in week 45 to **32.1** in week 46 in the North region, decreased from **22.2** in week 45 to **21.2** in week 46 in the South region, and increased from **23.0** in week 45 to **23.6** in week 46 in the Midlands And East region.
- **Lower Respiratory Tract Infections:** increased from **63.2** in week 45 to **68.7** in week 46 in the London region, increased from **136.8** in week 45 to **141.7** in week 46 in the North region, increased from **98.7** in week 45 to **101.4** in week 46 in the South region, and increased from **114.4** in week 45 to **119.1** in week 46 in the Midlands And East region.
- **Upper Respiratory Tract Infections:** increased from **145.4** in week 45 to **162.6** in week 46 in the London region, increased from **190.8** in week 45 to **202.9** in week 46 in the North region, increased from **151.8** in week 45 to **156.3** in week 46 in the South region, and increased from **173.4** in week 45 to **188.2** in week 46 in the Midlands And East region.
- **COVID-19:** decreased from **1.2** in week 45 to **0.7** in week 46 in the London region, decreased from **2.3** in week 45 to **1.9** in week 46 in the North region, decreased from **3.2** in week 45 to **1.8** in week 46 in the South region, and decreased from **2.1** in week 45 to **1.5** in week 46 in the Midlands And East region.

### Comment:

Overall rates of acute respiratory infections (ARI) have increased in all regions, but are at or below the seasonal average (page 6). The overall rate of influenza-like illness (ILI) have decreased, but remain at or below the seasonal average (pages 2 and 3), while rates of COVID-19 have decreased in all regions (page 5).


Exacerbations of chronic lung disease (ECLD) remain above the seasonal average (page 7). There has been an increase in lower respiratory tract infections (LRTI, page 7) among children aged under 1, driven largely by bronchiolitis (page 9). Rates of scabies (page 15) remain above the seasonal average.

This report includes a respiratory virology update. SARS-CoV-2 and RSV are the predominant circulating viruses detected by the UK Health Security Agency (UKHSA) Reference Virology Lab. Rates presented in this report are the number of new cases per 100,000 people by condition and region, with age-band also reported for acute respiratory infections (pages 3 to 11). The second Friday report which started in the pandemic has now ceased. The RCGP Weekly Return has reverted to reporting weekly.


## 2024 Focus



Please see page 19 for explanatory notes on the data.

### (A) Influenza-like illness: national incidence rate 2024 by region



### (B) RCGP/UKHSA Influenza Virology Swab Surveillance 2024



**(C) RCGP/UKHSA RSV, Influenza and SARS-CoV-2 Virology Swab Surveillance 2024 by viral strain****(D) Influenza-like illness: national incidence rate 2024 by age band**

**(E) Influenza-like illness: national incidence rate 2024 by age band**


This table shows the level of intensity of ILI by age band. MEM thresholds have been calculated separately for each age band - the ranges are shown in the table Threshold levels by age band.

Table 1	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34
1-4yrs	0.9	0.9	1.0	0.8	1.4	1.5	1.4	1.5	1.5	1.0	1.0	1.6	1.0	1.3	0.9	0.1	0.9	0.6
5-14yrs	1.6	2.0	1.7	1.2	1.1	0.4	1.1	1.2	1.0	1.0	0.6	0.9	0.8	0.4	0.3	0.3	0.2	0.4
15-64yrs	3.5	3.3	2.1	2.8	2.1	1.9	2.2	2.6	2.3	1.9	1.8	2.3	2.1	2.3	1.7	1.3	1.2	1.2
65+yrs	2.1	2.3	0.8	1.7	1.2	1.3	1.3	1.4	1.5	1.0	1.6	2.2	2.1	2.1	1.4	1.0	1.0	1.0
All ages	2.9	2.8	1.7	2.3	1.8	1.6	1.9	2.2	2.0	1.6	1.6	2.0	1.9	2.0	1.5	1.1	1.0	1.1



	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52
1-4yrs	0.6	0.7	0.9	3.0	2.1	2.2	2.6	4.2	4.3	4.0	1.9	4.7						
5-14yrs	0.2	0.4	0.4	1.2	1.8	1.5	1.5	1.7	2.0	1.3	1.9	2.9						
15-64yrs	1.0	1.7	1.8	2.5	2.8	3.6	4.0	4.4	4.1	4.1	4.3	4.1						
65+yrs	0.9	0.8	1.6	1.8	1.7	2.9	3.3	3.7	3.5	3.3	3.4	2.8						
All ages	0.9	1.3	1.5	2.3	2.5	3.2	3.6	3.9	3.8	3.6	3.8	3.7						

Table 2	Below Threshold <sup>1</sup>	Threshold to Medium <sup>2</sup>	Medium to High <sup>3</sup>	High to Very High <sup>4</sup>	Above Very High <sup>5</sup>
1-4yrs	<8.05	8.05 to 15.57	15.58 to 23.50	23.51 to 28.19	28.20+
5-14yrs	<6.53	6.53 to 15.55	15.56 to 32.18	32.19 to 44.39	44.40+
15-64yrs	<12.23	12.23 to 24.53	24.54 to 45.08	45.09 to 58.99	59.00+
65+yrs	<9.62	9.62 to 16.69	16.70 to 35.98	35.99 to 50.52	50.53+
All Ages	<10.25	10.25 to 21.69	21.70 to 38.77	38.78 to 50.11	50.12+

**Threshold levels**<sup>1</sup>Below baseline threshold<sup>2</sup>baseline threshold breach to < 40th percentile<sup>3</sup>40th to <90th percentile<sup>4</sup>90th to <97.5th percentile<sup>5</sup>97.5th+ percentile**(F) Acute Bronchitis and Bronchiolitis: national incidence rate 2024 by age band****Weekly Influenza-like illness and Acute Bronchitis and Bronchiolitis incidence rates per 100,000 persons**


Influenza-like illness		Acute Bronchitis and Bronchiolitis		Influenza-like illness		Acute Bronchitis and Bronchiolitis	
<1yr	2.8	466.3	London	4.8	6.0		
1-4yrs	4.7	49.0	North	3.9	9.7		
5-14yrs	2.9	0.6	South	3.1	7.6		
15-24yrs	4.2	1.4	Midlands And East	3.6	7.5		
25-44yrs	4.2	1.8	National	3.7	7.8		
45-64yrs	3.8	3.0					
65-74yrs	2.5	3.5					
75-84yrs	3.1	3.0					
85+yrs	3.4	4.3					
All ages	3.7	7.8					

\*\*The <1yr age band is not presented (Graph F).


**(G) COVID-19: national incidence rate 2024 by region****(H) COVID-19: national incidence rate 2024 by age band**

# 1. Respiratory Infections

## (I) Acute Respiratory Infections (ARI): national incidence rate 2024 by region




## (J) Acute Respiratory Infections (ARI): national incidence rate 2024 by age band




1. Respiratory Infections - *by region*

5yr Avg    National    South  
 North    Midlands And East  
 London


**Influenza-like illness (ILI)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average


1. Respiratory Infections - *by age band*

5yr Avg    All ages    5-14yrs  
 <1yr    15-64yrs  
 1-4yrs    65+yrs


**Influenza-like illness (ILI)**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD)**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI)**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




1. Respiratory Infections - *by region*

5yr Avg    National    South  
 North    Midlands And East  
 London


**Upper Respiratory Tract Infections (URTI)**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD) - Asthma Exacerbations**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD) - COPD Exacerbations**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average


1. Respiratory Infections - *by age band*

5yr Avg    All ages    5-14yrs  
 <1yr    15-64yrs  
 1-4yrs    65+yrs


**Upper Respiratory Tract Infections (URTI)**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average



**Exacerbations of Chronic Lung Disease (ECLD) - Asthma Exacerbations**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




**Exacerbations of Chronic Lung Disease (ECLD) - COPD Exacerbations**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average






1. Respiratory Infections - *by region*


**Lower Respiratory Tract Infections (LRTI) - Pneumonia**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Acute Bronchitis**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Bronchiolitis**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average

1. Respiratory Infections - *by age band*


**Lower Respiratory Tract Infections (LRTI) - Pneumonia**  
Weekly incidence (per 100,000 all regions) by age band  
for 2024 compared with 5 year average



**Lower Respiratory Tract Infections (LRTI) - Acute Bronchitis**  
Weekly incidence (per 100,000 all regions) by age band  
for 2024 compared with 5 year average




**Lower Respiratory Tract Infections (LRTI) - Bronchiolitis**  
Weekly incidence (per 100,000 all regions) by age band  
for 2024 compared with 5 year average




1. Respiratory Infections - *by region*

5yr Avg   National   South  
 North   Midlands And East  
 London


**Upper Respiratory Tract Infections (URTI) - Croup**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average



**Upper Respiratory Tract Infections (URTI) - Tonsillitis/Pharyngitis**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Otitis Media**  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average


1. Respiratory Infections - *by age band*

5yr Avg   All ages   5-14yrs  
 <1yr   15-64yrs  
 1-4yrs   65+yrs


**Upper Respiratory Tract Infections (URTI) - Croup**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Tonsillitis/Pharyngitis**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




**Upper Respiratory Tract Infections (URTI) - Otitis Media**  
 Weekly incidence (per 100,000 all regions) by age band  
 for 2024 compared with 5 year average




1. Respiratory Infections - *by region*


Upper Respiratory Tract Infections (URTI) - Sinusitis  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




Upper Respiratory Tract Infections (URTI) - Laryngitis  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average

1. Respiratory Infections - *by age band*

Upper Respiratory Tract Infections (URTI) - Sinusitis  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




Upper Respiratory Tract Infections (URTI) - Laryngitis  
 Weekly incidence (per 100,000 all ages) by region  
 for 2024 compared with 5 year average




## 2. Water & Food Borne Disorders

5yr Avg   National   North   London   South   Midlands And East


**Infectious Intestinal Disease (ICD10: A00-A09)**  
Weekly incidence (per 100,000 **all ages**) by region  
for 2024 compared with 5 year average




**Infectious Intestinal Disease (ICD10: A00-A09)**  
Weekly incidence (per 100,000 **0-4 years**) by region  
for 2024 compared with 5 year average



**Non-Infective Enteritis & Colitis (ICD10: K50-K52)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Viral Hepatitis (ICD10: B15-B19)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




### 3. Environmentally Sensitive Disorders

5yr Avg   National   North   London   South   Midlands And East


**Asthma (ICD10: J45-J46)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



**Disorders of Conjunctiva (ICD10: H10-H13)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Hayfever/Allergic Rhinitis (ICD10: J30)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




## 4. Vaccine Sensitive Disorders

5yr Avg   National   North   London   South   Midlands And East


**Measles (ICD10: B05)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Mumps (ICD10: B26)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



**Rubella (ICD10: B06)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Whooping Cough (ICD10: A37)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




## 5. Skin Contagions

**Bullous Dermatoses (ICD10: L10-L14)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Chickenpox (ICD10: B01)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




## 5. Skin Contagions (Continued)

5yr Avg   National   North   London   South   Midlands And East


**Herpes Simplex (ICD10: B00)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Herpes Zoster (ICD10: B02)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Infections of Skin & Subcutaneous Tissue (ICD10: L00-L08)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Scabies (ICD10: B86)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



**Symptoms involving Skin & Oth Integument Tiss (ICD10: R20-R23)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Impetigo (ICD10: L01)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




## 6. Disorders Affecting the Nervous System

5yr Avg   National   North   London   South   Midlands And East


**Disorders of The Peripheral Nervous System (ICD10: G50-G64,G70-G72)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



**Meningitis/Encephalitis(ICD10: A170-A171,A390,A38-A85,A87,G00-G05)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average




**Symptoms Involving Nervous & Musculoskeletal (ICD10: R25-R29)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



## 7. Genitourinary System Disorders

**Urinary Tract Infection/Cystitis (ICD10: N30,N390)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average







## 8. Other Disorders

5yr Avg   National   North   London   South   Midlands And East

**Strep Sore Throat, Scarlatina and Peritonsillar Abscess (ICD10: A38,J020,J36)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



**Infectious Mononucleosis (ICD10: B27)**  
Weekly incidence (per 100,000 all ages) by region  
for 2024 compared with 5 year average



## 8. Tabular Summary by Disease

	Week beginning Week ending		11/11/2024 17/11/2024		04/11/2024 10/11/2024		28/10/2024 03/11/2024		21/10/2024 27/10/2024	
Disease Name	Rate	Numer	Rate	Numer	Rate	Numer	Rate	Numer	Rate	Numer
Acute Bronchitis	2.4	433	2.5	432	2.1	356	2.0	339		
Acute respiratory infections (ARI)	295.0	52,701	280.6	49,275	253.3	43,708	264.9	43,926		
Allergic Rhinitis	5.7	1,020	5.8	1,025	5.9	1,011	5.9	972		
Asthma	11.4	2,037	11.2	1,970	9.8	1,685	9.7	1,613		
Bronchiolitis	5.4	964	5.0	879	3.6	626	3.1	507		
Bullous Dermatoses	0.2	32	0.2	41	0.2	28	0.1	21		
Chickenpox	2.4	429	2.7	473	2.4	415	2.9	475		
Conjunctival Disorders	12.5	2,231	12.2	2,134	11.4	1,973	12.2	2,016		
COVID-19	1.5	275	2.3	406	3.0	516	4.5	739		
Croup	4.0	722	3.7	643	3.8	651	4.2	691		
ECLD - Asthma exacerbations	15.0	2,682	15.0	2,637	13.5	2,338	13.8	2,290		
ECLD - COPD exacerbations	8.2	1,459	8.1	1,431	7.8	1,344	7.9	1,309		
Exacerbations of chronic lung disease	22.9	4,096	22.9	4,018	21.1	3,642	21.4	3,555		
Herpes Simplex	2.8	500	2.7	475	2.4	413	2.6	435		
Herpes Zoster	4.6	824	5.0	873	5.0	860	5.3	883		
Impetigo	4.1	739	4.3	752	3.5	596	4.0	662		
Infectious Intestinal Diseases	7.3	1,299	7.3	1,278	6.4	1,096	6.9	1,147		
Infectious Mononucleosis	0.3	55	0.4	62	0.2	29	0.3	45		
Influenza-like illness	3.7	669	3.8	665	3.6	618	3.8	625		
Laryngitis	1.1	189	1.2	206	1.0	179	1.0	172		
Lower respiratory tract infections	109.1	19,487	104.6	18,371	93.5	16,130	95.0	15,749		
Measles	0.1	15	0.0	6	0.0	8	0.0	7		
Meningitis and Encephalitis	0.2	29	0.1	19	0.1	20	0.1	12		
Mumps	0.1	9	0.1	14	0.1	15	0.1	9		
Non-infective Enteritis and Colitis	2.6	464	2.9	505	2.5	433	3.0	495		
Otitis Media	22.4	4,008	20.4	3,587	18.4	3,176	19.2	3,188		
Peripheral Nervous Disease	18.3	3,273	18.6	3,271	16.6	2,862	18.0	2,984		
Pneumonia	3.8	681	3.6	634	3.4	582	3.7	614		
Rubella	0.0	0	0.0	1	0.0	2	0.0	1		
Scabies	3.3	594	3.7	649	3.8	662	3.3	544		
Sinusitis	17.9	3,196	17.9	3,152	16.7	2,884	16.0	2,656		
Skin and Subcutaneous Tissue Infections	83.3	14,871	85.1	14,948	85.3	14,717	85.9	14,249		
Strep Throat and Peritonsillar Abscess	1.4	243	1.2	204	1.1	186	1.3	213		
Symptoms involving musculoskeletal	15.0	2,681	14.9	2,610	13.8	2,383	14.7	2,430		
Symptoms involving Skin and Integument Tissues	114.7	20,491	116.4	20,441	110.2	19,019	113.7	18,848		
Tonsillitis/Pharyngitis	31.4	5,611	31.3	5,496	27.0	4,665	29.3	4,859		
Upper respiratory tract infections	176.6	31,550	165.2	29,014	149.0	25,708	156.4	25,932		
Urinary Tract Infections	26.4	4,718	27.5	4,822	24.5	4,225	25.4	4,205		
Viral Hepatitis	0.2	35	0.3	50	0.2	38	0.3	43		
Whooping Cough	0.2	28	0.2	31	0.2	32	0.3	48		
<b>Practice Count</b>		<b>1,688</b>		<b>1,671</b>		<b>1,645</b>		<b>1,589</b>		
<b>Denom</b>		<b>17,862,856</b>		<b>17,561,804</b>		<b>17,256,820</b>		<b>16,579,817</b>		

## FURTHER INFORMATION:

### About the report

#### Focus

The first two pages of data within this report focus on influenza-like illness and virology data, in order to provide information about seasonal influenza and early warnings of any epidemic.

#### Rate calculation

Each weekly incidence rate is presented per 100,000 population. All presentations are for males and females, and for all age bands, unless otherwise stated.

The denominator used for this report is taken from our most recent extract of data from GP practice systems, and includes all patients currently registered with eligible practices. The denominator varies week-on-week as patients register and deregister; it may also be the case that all patients from an individual practice are excluded because of problems with the data extraction from that practice in a specific week. As stated above, patients who have withheld consent for data-sharing are excluded.

In addition to the national rate, we present data for the four NHS England regions: North; Midlands and East; South; and London.

#### Five-year averages

Weekly rates are set against a five-year average (navy blue lines), previously we reported against a ten-year average. The change to a five-year average was made because longer-term trends in the incidence of disease have led to weekly rates for certain diseases becoming increasingly divergent from their ten-year average. The use of five-year averages lessens this effect and enables more meaningful comparison.

#### Threshold calculation for influenza-like illness (ILI)

We are now using the Moving Epidemic Method (MEM) to calculate threshold and intensity levels for influenza-like illness (Graph A, page 2 and Table E, page 4 of this report). MEM works by identifying seasonal epidemic peaks and then calculates thresholds and intensity levels based on the pre and post epidemic values. This allows us to report the severity of ILI against multiple thresholds, rather than a simple comparison with the five-year average as the wide variation in ILI year on year, especially during the seasonal peak, makes the average less representative.

In addition to the All Ages thresholds, we have also calculated thresholds for four age bands: those aged 1-4, 5-14, 15-64 and those aged 65 and over. ILI incidence rates vary among different age bands, and the age-specific thresholds allow us to highlight epidemics where ILI disproportionately affects a particular age band.

This methodology is used by the European Centre for Disease Prevention and Control to standardise reporting of influenza activity across Europe, and is also in use by the UK Health Security Agency. Full details of the methodology can be found in: Vega *et al.* (2012) Influenza surveillance in Europe: establishing epidemic thresholds by the moving epidemic method. Influenza and Other Respiratory Viruses 7(4), 546–558.

Both the *all-ages* thresholds and the *age-specific* thresholds are shown in Table E, page 4. Five years of data were used for *all-ages* and *age-specific* thresholds calculation (winter seasons 2015/16, 2016/17, 2017/18, 2018/19 and 2022/23, excluding 2019/20, 2020/21 and 2021/22).

## About the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC)

### Acknowledgement:

Staff from the Data Science department at the National Physical Laboratory (<https://www.npl.co.uk/data-science>) assisted in the provision of and extension of the primary care national surveillance reports during the 2020 SARS-CoV-2 pandemic; as well as adding resilience.

### What we do

The RCGP RSC was established in 1957, with the current name in use since 2009. The Centre is an internationally renowned source of information, analysis and interpretation concerning the onset, patterns, prevalence and trends over time of morbidity in primary care. The RSC is an active research and surveillance unit that collects and monitors data; its most important research is the surveillance of influenza and the monitoring of vaccine effectiveness.

The RSC data and analytics hub is housed at the Oxford-Royal College of General Practitioners Research and Surveillance Centre.

Further information about the RSC can be found on our website:

<http://www.rcgp.org.uk/rsc>

### Our data extraction process and information governance

Data are extracted twice weekly from practice systems by Magentus data management and EMIS-X Analytics (EXA) on the RCGP's behalf. Patients who have withheld consent for data sharing are excluded from the extraction process.

Data are pseudonymised as close to source as possible. Data are held on secure servers at the RCGP data and analytics hub at the Oxford-Royal College of General Practitioners Research and Surveillance Centre. Both Magentus data management and the University of Oxford are Registered and compliant with the Data Protection Act and fully compliant with all relevant NHS Digital data information governance best practice.

### What the data is used for

The RCGP RSC has been providing reports weekly about health and disease, called the Weekly Returns Service (WRS) since 1964. The WRS monitors the number of patients consulting with new episodes of illness classified by diagnosis in England and provides weekly incidence rates per 100,000 population for these new episodes of illness. It is the key primary care element of the national disease monitoring systems run by the UK Health Security Agency. The bulletin can be found at the following URL:

<https://www.gov.uk/government/collections/syndromic-surveillance-systems-and-analyses>

In addition to the WRS, the data is used for other research studies. Any other uses of the data for research follow ethical approval or agreement from NIHR proportionate review, and where relevant Health Research Authority Confidential Advisory Group advice that further approval is not needed. Full details can be found on our website:

<http://www.rcgp.org.uk/rsc>

### For further information

For further information about the work of the RSC, or if you would like to be included on our email notification list, please contact:

RCGP Research & Surveillance Centre  
Policy, Research and Campaigns  
Royal College of General Practitioners  
30 Euston Square, London, NW1 2FB  
Tel: switchboard 020 3188 7400

Director: Professor Simon de Lusignan

[MedicalDirectorRSC@rcgp.org.uk](mailto:MedicalDirectorRSC@rcgp.org.uk)

University of Oxford  
Nuffield Department of Primary Care Health Sciences  
Gibson Building  
Radcliffe Observatory  
Woodstock Road  
Oxford OX2 6GG

